Medium-term Management Plan

To realize its "Vision for 2031," Mochida Pharmaceutical Group has adopted the 22-24 Medium-term Management Plan (22-24 MTP) as an action plan for issues to be addressed over the three-year period from FY2022 to FY2024 from the perspective of the sustainable enhancement of corporate value and in alignment with its Group's Basic Sustainability Policy.
The business environment surrounding the pharmaceutical industry is expected to become even more challenging going forward, given the continued promotion of policies to curb drug costs against the backdrop of the problem of securing financial resources for social security expenses. The Group will continue to invest in growth to realize its "Vision for 2031," in spite of the expectation of a temporary deterioration in earnings during the 22-24 MTP period.

Medium-term Management Plan Policy for the fiscal years 2022 through 2024

We will respond to medical and healthcare needs with concentration of the total power of the Group covering research and development, manufacturing and marketing, pursue sustainable growth by promoting selection and focusing processes, and restructure the earnings structure to respond to further environmental changes.

Key issues to be addressed

During the 22-24 MTP period, we will focus on the following issues under the theme of innovation creation and productivity improvement.

1. Maximization of profits in targeted areas with a focus on new drugs

To concentrate our resources on the targeted areas (cardiovascular medicine, obstetrics and gynecology, psychiatry, and gastroenterology) to maintain our prominence and maximize earnings from new drugs in our core pharmaceutical business
To continually work to maintain a stable supply and proper quality of our products, while promoting improvements in our cost structure by reducing procurement costs and reviewing our product lineup

2. Continuous investment in growth to realize the "Vision for 2031"

To pursue investments in business activities that will lead to future competitiveness;

To work to expand and promote the biomaterials business and aim for an early launch
To incorporate new drug discovery modalities, such as cells, nucleic acids, and genes. To give priority to development especially in the field of regenerative medicine products

3. Strengthening of the corporate organization to create innovation and improve productivity

To harmonize and coordinate four approaches: optimization of business processes and business quality level, promotion of digital transformation, institutional reform, and the promotion of facility management, in order to achieve efficient organizational operations and increase corporate value
To continue to support capacity development to improve performance and promote the development of human resources that will drive innovation
To focus on strengthening our human resource management system to ensure development and vitalization of human resources
To work to improve our organizational capabilities by optimizing our personnel strategy and allocation, while strengthening interdepartmental cooperation